ethyl 2,3-dioxobutanoate 2-(4-hydroxyphenyl)hydrazone | 132577-23-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2,3-dioxobutanoate 2-(4-hydroxyphenyl)hydrazone
• 英文别名: ethyl 2-(2-(4-hydroxyphenyl)hydrazono)-3-oxobutanoate；ethyl 2-((4-hydroxyphenyl)hydrazono)-3-oxobutanoate；AHE-4；ethyl 2-[(4-hydroxyphenyl)hydrazinylidene]-3-oxobutanoate
• CAS: 132577-23-2
• 化学式: C₁₂H₁₄N₂O₄
• 分子量: 250.254
• InChiKey: AIYVXIOVOIUOBN-UHFFFAOYSA-N

物化性质

• 熔点：
  198 °C(Solv: ethanol (64-17-5))
• 沸点：
  395.1±44.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  18.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  87.99
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  ethyl 2,3-dioxobutanoate 2-(4-hydroxyphenyl)hydrazone 在 吗啉 、 lithium hydroxide monohydrate 、 ammonium acetate 、 水 、 sulfur 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 17.25h， 生成 5-amino-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylic acid
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME SONDES D'IMAGERIE DE PATHOLOGIE TAU

  摘要：

  Formula I中的吡啶嗪酮化合物：（I），其中：R'是烷基或Ar，可选择地取代为至少一个烷基，卤素，羟基，烷氧基，卤代烷氧基，酸，酯，氨基，硝基，酰胺，或烷氧基卤代；2 R独立地是烷基，炔基，酯，氨基，酰胺，酸，芳基，杂环芳基，氨基烷基，-C(=0)烷基，-C(=0)芳基，-C(=0)杂环芳基，-C(=0)杂环烷基，-C(=0)杂环烷基Ar，-C(=0)(CH2)n卤代，-C(=0)(CH2)n杂环基，或-SC^Ar，可选择地取代为至少一个烷基，烷基卤代，卤素，硝基，芳基，杂环芳基，或杂环芳基(CH2)n卤代；R3和R4独立地是氢，烷基，烯基，炔基，芳基，杂环芳基；Ar是芳基，杂环芳基，环烷基，杂环烷基基团；n是0-10之间的整数；或其放射标记衍生物。所述化合物可用作阿尔茨海默病中Tau病理的成像探针。还描述了制备这种化合物的组成物和方法。

  公开号：

  WO2013090497A1
• 作为产物：
  描述：

  对氨基苯酚 、 乙酰乙酸乙酯 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 2.33h， 以6 g的产率得到ethyl 2,3-dioxobutanoate 2-(4-hydroxyphenyl)hydrazone
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME SONDES D'IMAGERIE DE PATHOLOGIE TAU

  摘要：

  Formula I中的吡啶嗪酮化合物：（I），其中：R'是烷基或Ar，可选择地取代为至少一个烷基，卤素，羟基，烷氧基，卤代烷氧基，酸，酯，氨基，硝基，酰胺，或烷氧基卤代；2 R独立地是烷基，炔基，酯，氨基，酰胺，酸，芳基，杂环芳基，氨基烷基，-C(=0)烷基，-C(=0)芳基，-C(=0)杂环芳基，-C(=0)杂环烷基，-C(=0)杂环烷基Ar，-C(=0)(CH2)n卤代，-C(=0)(CH2)n杂环基，或-SC^Ar，可选择地取代为至少一个烷基，烷基卤代，卤素，硝基，芳基，杂环芳基，或杂环芳基(CH2)n卤代；R3和R4独立地是氢，烷基，烯基，炔基，芳基，杂环芳基；Ar是芳基，杂环芳基，环烷基，杂环烷基基团；n是0-10之间的整数；或其放射标记衍生物。所述化合物可用作阿尔茨海默病中Tau病理的成像探针。还描述了制备这种化合物的组成物和方法。

  公开号：

  WO2013090497A1

文献信息

• A family of substituted hydrazonoisoxazolones with potential biological properties
  作者：Carlos Bustos、Elies Molins、Juan-Guillermo Cárcamo、Marcelo N. Aguilar、Christian Sánchez、Ignacio Moreno-Villoslada、Hiroyuki Nishide、Ximena Zarate、Eduardo Schott

  DOI：10.1039/c5nj02604k

  日期：——

  activity. The most active isoxazolones were used in reverse transcription polymerase chain reaction (RT-PCR) experiments to determine the effect on the expression levels on mRNA encoding using the anti-apoptotic, Bcl 2, pro-apoptotic, Bax, and the proliferation inhibition, p21WAF-1, proteins. Therefore, it was possible to fully characterize the complete library of 15 isoxazolones and to show that most

  已经报道了一种新的3,4,5-三取代异恶唑酮的合成，表征和生物学研究，从而研究了一系列（Z）-3-甲基-4-（2-（R-苯基）苯二甲叉基）异恶唑-5（通过β-二酮hydr与氯化铵反应制备了4 H）-one。所有产品均使用EA，UV-Vis，FT-IR，1 H-NMR，13进行表征C-NMR光谱和HMBC。通过X射线衍射方法解析了三种化合物的晶体和分子结构。进行密度泛函理论（DFT）和时变DFT（TDDFT）计算，以更好地解释这些新合成的化合物的实验行为。此外，通过MTT还原法测试了在人早幼粒细胞白血病细胞HL-60中的细胞毒性和抗增殖作用的报道，表明大多数新合成的化合物具有重要的抗肿瘤活性。最活跃isoxazolones是在反转录聚合酶链反应（RT-PCR）实验中使用，以确定对表达水平的影响米使用抗凋亡Bcl 2，促凋亡Bax和增殖抑制蛋白p21 WAF-1编码的RNA 。因此，有可能完全
• Synthesis and bio-evaluation of aryl hydrazono esters for oviposition responses in Aedes albopictus
  作者：Prabal Bandyopadhyay、Lopamudra Guha、T. Seenivasagan、Manisha Sathe、Pratibha Sharma、B.D. Parashar、M.P. Kaushik

  DOI：10.1016/j.bmcl.2010.11.101

  日期：2011.1

  A novel series of aryl hydrazono esters (AHE) (1-13) were synthesized (yield 76-98%) to study the oviposition responses in Aedes albopictus (Skuse) mosquitoes for the first time. At a concentration of 10 mu g ml(-1) in dual choice experiment, among the screened compounds, AHE-12 showed remarkable oviposition attractant activity with an oviposition activity index (OAI) of +0.299 (greater than 95% confidence limit) comparable to p-cresol (OAI +0.320) which is well-reported oviposition attractant for Aedes aegypti. Conversely, AHE-10 exhibited highest oviposition deterrent activity with OAI -0.247. The possible utilization of these compounds will be in integrated vector management strategies. (C) 2010 Elsevier Ltd. All rights reserved.
• Amir, Mohd; Agarwal, Rajesh, Journal of the Indian Chemical Society, 1997, vol. 74, # 2, p. 154 - 155
  作者：Amir, Mohd、Agarwal, Rajesh

  DOI：——

  日期：——
• Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure–activity relationship leads to selection of candidates with desirable in vivo properties
  作者：Carlo Ballatore、Alex Crowe、Francesco Piscitelli、Michael James、Kevin Lou、Gabrielle Rossidivito、Yuemang Yao、John Q. Trojanowski、Virginia M.-Y. Lee、Kurt R. Brunden、Amos B. Smith

  DOI：10.1016/j.bmc.2012.05.027

  日期：2012.7

  Previous studies demonstrated that members of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors exhibit a promising combination of in vitro activity as well as favorable pharmacokinetic properties (i.e., brain-penetration and oral bioavailability). Here we report the synthesis and evaluation of several new analogues. These studies indicate that the thienopyridazine core is essential for inhibition of tau fibrillization in vitro, while the choice of the appropriate scaffold decoration is critical to impart desirable ADME-PK properties. Among the active, brain-penetrant ATPZ inhibitors evaluated, 5-amino-N-cyclopropyl-3-(4-fluorophenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide (43) was selected to undergo maximum tolerated dose and one-month tolerability testing in mice. The latter studies revealed that this compound is well-tolerated with no notable side-effects at an oral dose of 50 mg/kg/day. (C) 2012 Elsevier Ltd. All rights reserved.
• 2-Aminothienopyridazines as Novel Adenosine A₁ Receptor Allosteric Modulators and Antagonists
  作者：Gemma N. Ferguson、Celine Valant、James Horne、Heidi Figler、Bernard L. Flynn、Joel Linden、David K. Chalmers、Patrick M. Sexton、Arthur Christopoulos、Peter J. Scammells

  DOI：10.1021/jm800557d

  日期：2008.10.9

  A pharmacophore-based screen identified 32 compounds including ethyl 5-amino-3-(4-tert-butylphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylate (8) as a new allosteric modulator of the adenosine A(1) receptor (A(1)AR). On the basis of this lead, various derivatives were prepared and evaluated for activity at the human A(1)AR. A number of the test compounds allosterically stabilized agonist-receptor-G protein ternary complexes in dissociation kinetic assays, but were found to be more potent as antagonists in subsequent functional assays of ERK1/2 phosphorylation. Additional experiments on the most potent antagonist, 13b, investigating A(1)AR-mediated [S-35]GTP gamma S binding and [H-3]CCPA equilibrium binding confirmed its antagonistic mode of action and also identified inverse agonism. This study has thus identified a new class of A(1)AR antagonists that can also recognize the receptor's allosteric site with lower potency.